{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T17:34:23Z","timestamp":1785692063229,"version":"3.56.0"},"reference-count":59,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11\/2017 and 06\/2022. We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarker-guided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody\u2013drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge.<\/jats:p>","DOI":"10.3390\/ijms25042345","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T08:02:17Z","timestamp":1708070537000},"page":"2345","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9338-9646","authenticated-orcid":false,"given":"Fabian B. T.","family":"Kraus","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"},{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1786-5890","authenticated-orcid":false,"given":"Elena","family":"Sultova","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jung","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Comprehensive Cancer Center Munich, LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-877X","authenticated-orcid":false,"given":"Christina V.","family":"Tauber","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kumbrink","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Comprehensive Cancer Center Munich, LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rudelius","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Comprehensive Cancer Center Munich, LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Comprehensive Cancer Center Munich, LMU University Hospital, Ludwig Maximilians University (LMU), 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp A.","family":"Greif","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany"},{"name":"German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Chelariu-Raicu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6589-4736","authenticated-orcid":false,"given":"Bastian","family":"Czogalla","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wuerstlein","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-4350","authenticated-orcid":false,"given":"Fabian","family":"Trillsch","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Comprehensive Cancer Center Munich, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"ref_1","unstructured":"Bruni, L.A.G., Serrano, B., Mena, M., Collado, J.J., G\u00f3mez, D., Mu\u00f1oz, J., Bosch, F.X., and de Sanjos\u00e9, S. (2023). Human Papillomavirus and Related Diseases in the World, ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Summary Report 10 March 2023."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.gendis.2022.09.014","article-title":"Cervical cancer: A tale from HPV infection to PARP inhibitors","volume":"10","author":"Mann","year":"2023","journal-title":"Genes Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Balasubramaniam, S.D., Balakrishnan, V., Oon, C.E., and Kaur, G. (2019). Key Molecular Events in Cervical Cancer Development. Medicina, 55.","DOI":"10.3390\/medicina55070384"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00432-023-05511-6","article-title":"Human papillomavirus E7 protein induces homologous recombination defects and PARPi sensitivity","volume":"150","author":"He","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000052951","article-title":"Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association","volume":"52","author":"Chung","year":"2001","journal-title":"Gynecol. Obs. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/00003081-196712000-00002","article-title":"Natural history of cervical intraepithelial neoplasia","volume":"10","author":"Richart","year":"1967","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3332\/ecancer.2015.531","article-title":"VIN usual type-from the past to the future","volume":"9","author":"Preti","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/jmv.27311","article-title":"A retrospective study of cytology and HPV genotypes results of 3229 vaginal intraepithelial neoplasia patients","volume":"94","author":"Ao","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/AOG.0b013e31819bd6e0","article-title":"Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors","volume":"113","author":"Smith","year":"2009","journal-title":"Obs. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Borella, F., Preti, M., Bertero, L., Collemi, G., Castellano, I., Cassoni, P., Cosma, S., Carosso, A.R., Bevilacqua, F., and Gallio, N. (2020). Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010190"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2012.45.3605","article-title":"Personalizing oncology: Perspectives and prospects","volume":"31","author":"Mendelsohn","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/jcm4020260","article-title":"HPV Carcinomas in Immunocompromised Patients","volume":"4","author":"Reusser","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"996495","DOI":"10.3389\/fonc.2022.996495","article-title":"Immune checkpoint inhibitors in advanced and recurrent\/metastatic cervical cancer","volume":"12","author":"Han","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): A randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2023","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S1276","DOI":"10.1016\/j.annonc.2023.10.029","article-title":"LBA9 innovaTV 301\/ENGOT-cx12\/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator\u2019s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer","volume":"34","author":"Vergote","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00432-022-04114-x","article-title":"Expression pattern and prognostic potential of histamine receptors in epithelial ovarian cancer","volume":"149","author":"Kraus","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Delord","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Aust, S., Schwameis, R., Gagic, T., Mullauer, L., Langthaler, E., Prager, G., Grech, C., Reinthaller, A., Krainer, M., and Pils, D. (2020). Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12030548"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2016.02.024","article-title":"Initiation of a formalized precision medicine program in gynecologic oncology","volume":"141","author":"Gunderson","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ygyno.2016.02.021","article-title":"Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers","volume":"141","author":"Hirshfield","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1060","DOI":"10.1634\/theoncologist.2019-0904","article-title":"Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform","volume":"25","author":"Taghizadeh","year":"2020","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Prieto-Potin, I., Idrovo, F., Suarez-Gauthier, A., Diaz-Blazquez, M., Astilleros-Blanco de Cordova, L., Chamizo, C., Zazo, S., Carvajal, N., Lopez-Sanchez, A., and Perez-Buira, S. (2022). Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. Diagnostics, 12.","DOI":"10.3390\/diagnostics12081903"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00432-022-04165-0","article-title":"Lessons learned: The first consecutive 1000 patients of the CCCMunich(LMU) Molecular Tumor Board","volume":"149","author":"Heinrich","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","volume":"38","author":"Flaherty","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Maruthi, V.K., Khazaeli, M., Jeyachandran, D., and Desouki, M.M. (2022). The Clinical Utility and Impact of Next Generation Sequencing in Gynecologic Cancers. Cancers, 14.","DOI":"10.3390\/cancers14051352"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdz088","article-title":"Molecular screening to select therapy for advanced cancer?","volume":"30","author":"Tannock","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1192762","DOI":"10.3389\/fmed.2023.1192762","article-title":"Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: A systematic review and meta-analysis","volume":"10","author":"Fitzsimmons","year":"2023","journal-title":"Front. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/1538-7445.AM2015-2662","article-title":"Abstract 2662: A dual PI3K\/mTOR inhibitor as potential therapeutic option for vulvar cancer","volume":"75","author":"Rodrigues","year":"2015","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00280-016-3064-0","article-title":"A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I","volume":"78","author":"Erlich","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_40","first-page":"6579715","article-title":"Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib","volume":"2022","author":"Gross","year":"2022","journal-title":"Case Rep. Obs. Gynecol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2016.05.003","article-title":"PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials","volume":"142","author":"Crafton","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"a026617","DOI":"10.1101\/cshperspect.a026617","article-title":"Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution","volume":"7","author":"Venkatesan","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tan, S.H., Sapari, N.S., Miao, H., Hartman, M., Loh, M., Chng, W.J., Iau, P., Buhari, S.A., Soong, R., and Lee, S.C. (2015). High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142466"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/2159-8290.CD-19-1508","article-title":"The Evolutionary Origins of Recurrent Pancreatic Cancer","volume":"10","author":"Sakamoto","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s11538-017-0359-1","article-title":"Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy","volume":"79","author":"Cho","year":"2017","journal-title":"Bull. Math. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","article-title":"Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing","volume":"182","author":"Maynard","year":"2020","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fran\u00e7a, G.S., Baron, M., Pour, M., King, B.R., Rao, A., Misirlioglu, S., Barkley, D., Dolgalev, I., Ho-Tang, K., and Avital, G. (2022). Drug-induced adaptation along a resistance continuum in cancer cells. bioRxiv.","DOI":"10.1101\/2022.06.21.496830"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ccell.2023.02.019","article-title":"Transcriptome analysis reveals tumor microenvironment changes in glioblastoma","volume":"41","author":"Hoogstrate","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"djv135","DOI":"10.1093\/jnci\/djv135","article-title":"Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy","volume":"107","author":"Challagundla","year":"2015","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Casolino, R., Beer, P.A., Chakravarty, D., Davis, M.B., Malapelle, U., Mazzarella, L., Normanno, N., Pauli, C., Subbiah, V., and Turnbull, C. (2024). Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. CA Cancer J. Clin., 1\u201322.","DOI":"10.3322\/caac.21825"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Crimini, E., Repetto, M., Tarantino, P., Ascione, L., Antonarelli, G., Rocco, E.G., Barberis, M., Mazzarella, L., and Curigliano, G. (2022). Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. Cancers, 14.","DOI":"10.3390\/cancers14133193"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Sultova, E., Westphalen, C.B., Jung, A., Kumbrink, J., Kirchner, T., Mayr, D., Rudelius, M., Ormanns, S., Heinemann, V., and Metzeler, K.H. (2021). Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040733"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1634\/theoncologist.2016-0049","article-title":"Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers","volume":"21","author":"Hirshfield","year":"2016","journal-title":"Oncologist"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2021.07.017","article-title":"Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study","volume":"163","author":"Arend","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.6004\/jadpro.2023.14.3.17","article-title":"The Role of Biomarkers in Guiding Clinical Decision-Making in Oncology","volume":"14","author":"Moore","year":"2023","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: Current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_58","first-page":"2123","article-title":"Cytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion","volume":"7","author":"Fu","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/4\/2345\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:00:52Z","timestamp":1760104852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/4\/2345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25042345"],"URL":"https:\/\/doi.org\/10.3390\/ijms25042345","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}